vidarabine has been researched along with Histiocytosis, Langerhans-Cell in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Attarbaschi, A; Gadner, H; Grois, N; Holter, W; Matthes-Martin, S; Minkov, M; Ouachee, M; Steiner, M; Unger, E; Vormoor, J; Wawer, A; Woessmann, W | 1 |
| Attarbaschi, A; Fritsch, G; Gadner, H; Lawitschka, A; Lion, T; Matthes-Martin, S; Minkov, M; Mittheisz, E; Steiner, M; Zoubek, A | 1 |
2 other study(ies) available for vidarabine and Histiocytosis, Langerhans-Cell
| Article | Year |
|---|---|
Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning.
Topics: Female; Graft Survival; Graft vs Host Disease; Histiocytosis, Langerhans-Cell; Humans; Infant; Langerhans Cells; Male; Melphalan; Prognosis; Salvage Therapy; Stem Cell Transplantation; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2005 |
Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Combined Modality Therapy; Drug Therapy, Combination; Etoposide; Female; Graft Survival; Histiocytosis, Langerhans-Cell; Humans; Infant; Lymphocyte Transfusion; Lymphohistiocytosis, Hemophagocytic; Melphalan; Prednisone; Remission Induction; T-Lymphocyte Subsets; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Vinblastine | 2007 |